Bioengineered Protein Drugs Market: Growth Analysis for 2023-2030

1
Bioengineered Protein Drugs Market Growth
Analysis for 2023-2030 Triton Market Research
presents the Global Bioengineered Protein Drugs
Market report sectioned by Type (Blood Factors
and Peptide Antibiotics, Monoclonal Antibodies,
Fusion Proteins, Therapeutic Enzymes, Peptide
Hormones, Vaccines (Excluding COVID-19),
Cytokines), Disease (Infectious Diseases,
Autoimmune Diseases and Other Immunodeficiency
Disorders, Solid Tumors, Growth Hormone
Disorders, Enzyme Disorders, and Infertility,
Diabetes, Blood Disorders, Other Diseases), and
Regional Outlook (Asia- Pacific, Latin America,
North America, Middle East and Africa,
Europe). The report further includes the Market
Summary, Industry Outlook, Impact of COVID-19,
Key Insights, Porters Five Forces Analysis,
Market Attractiveness Index, Vendor Scorecard,
Regulatory Framework, Key Market Strategies,
Drivers, Challenges, Opportunities, Competitive
Landscape, Research Methodology Scope, Global
Market Size, Forecasts Analysis
(2023-2030). Based on Tritons report, the global
bioengineered protein market is expected to
advance with a CAGR of 7.7 during the forecast
period 2023-2030. Request Free Sample
Report https//www.tritonmarketresearch.com/repor
ts/bioengineered-protein-drugs-
marketrequest-free-sample Proteins are
essential in offering structural support to the
body, along with preventing diseases.
Bioengineered proteins are produced via a genetic
modification to regulate protein transport and
treat injuries and other diseases. The
advancements in biotechnology and protein
engineering are expected to open new avenues for
the studied market. In recent years, the advent
of recombinant DNA technology has enabled
manufacturers to develop large quantities of
bioengineered protein drugs. For instance, blood
products, earlier extracted from human plasma,
are manufactured using DNA technology. Moreover,
this technology helps elevate the functionality
and production capacity of the product. Thus,
such developments are expected to increase their
adoption over the forecast period. However, the
markets growth is restrained mainly owing to the
high costs associated with these drugs
development and complications during
treatments. North America leads the bioengineered
protein drugs market. The regions robust growth
is mainly owing to well-developed diagnosis and
treatment facilities. Moreover, the rise in
chronic diseases and growth in the elderly
population base adds to the demand for
bioengineered protein medications. Another
development is the adoption of novel drugs
2
produced using advanced technologies that fuel
the adoption of these drugs. Hence, the
above-mentioned factors propel the North American
market on a growth path. The leading companies in
the bioengineered protein drugs market include
Abbott Laboratories, Amgen Inc, Merc Co Inc,
Eli Lilly and Company, Bayer Healthcare
Pharmaceuticals LLC, Johnson Johnson, Baxter
International Inc, F Hoffmann-La Roche, Fresenius
Kabi, and GlaxoSmithKline. Given the vast size of
the bioengineered protein drugs market, almost
all prominent companies have their presence or
are developing therapies to gain a competitive
edge. This indicates the competition level to be
high and significantly affected by new product
launches. Besides, the RD of novel therapies and
technologies adds to the intense competition. As
per estimates, protein-based drugs account for a
significant share of global pharmaceutical sales,
which is expected to influence manufacturers to
increase their development activities. Contact
Us sales_at_tritonmarketresearch.com Phone 44
7441 911839